Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Farkasgyepu – page 4

162 clinical trials in Farkasgyepu, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Farkasgyepu at a glance
162
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

162 trials in Farkasgyepu

Open in trial search

Study on the Safety and Benefits of Recombinant Human Plasma Gelsolin for Patients with Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS)

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Human Plasma Gelsolin, Recombinant
  • Sponsor:Bioaegis Therapeutics Inc.

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis Who Have Not Responded Well to Previous Biologic Treatments

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cardiovascular disorder+3

Not yet recruiting

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational
Countries:HungaryHungary
  • Participants:18–64 years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Obesity+1

Not yet recruiting

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Type 2 diabetes mellitus+2

Not yet recruiting

Efficacy and Safety of Olatorepatide in Adults with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Obesity

Not yet recruiting

KAI-9531 in Adults With Obesity or Overweight and Diabetes

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:HRS 9531
  • Sponsor:Kailera Therapeutics Inc.

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the effectiveness and safety of JNJ-88545223 in people with active psoriatic arthritis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-88545223
  • Sponsor:Janssen - Cilag International

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Rheumatoid arthritis

Not yet recruiting

Study comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:Mabxience Research S.L.

Osteoporosis postmenopausal

Not yet recruiting

Study on the Effects of BP16 and Denosumab in Women with Post-Menopausal Osteoporosis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Curateq Biologics Private Limited

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Farkasgyepu

What the registry says about research in the country

01 Lung Cancer Immunotherapy

Innovative clinical trials exploring immunotherapy combinations for advanced non-small cell lung cancer (NSCLC), focusing on treatment options for patients with various stages of the disease.

  • Novel immunotherapy combinations
  • PD-L1 targeted therapies
  • First-line treatment strategies

Research aims to improve survival rates and treatment outcomes through targeted immunological approaches.

02 Advanced NSCLC Treatments

Studies evaluating targeted therapies for specific mutations in non-small cell lung cancer, including HER2 and KRAS G12C mutations.

  • Mutation-specific treatments
  • Combination therapy approaches
  • Novel drug development

Investigations focus on personalized treatment strategies for different NSCLC subtypes.

03 Small Cell Lung Cancer Research

Clinical trials examining new therapeutic options for small cell lung cancer, including novel drug combinations and comparative effectiveness studies.

  • Single-agent therapies
  • Combination treatments
  • Survival outcome studies

Research focuses on improving treatment options for patients with relapsed SCLC.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.